Mechanism of tremelimumab

Tremelimumab (tremelimumab) is a fully human monoclonal antibody mainly used to treat hepatocellular carcinoma (uHCC) and non-small cell lung cancer (NSCLC). It is designed to attach to and block CTLA-4. CTLA-4 is a negative regulator of T cell activity. Texitumumab is a monoclonal antibody that binds CTLA-4 and blocks the interaction with its ligands CD80 and CD86, releasing CTLA-4-mediated inhibition of T cell activation. In synergistic mouse tumor models, blocking CTLA-4 activity resulted in reduced tumor growth and increased T cell proliferation in tumors.